Results 51 to 60 of about 74,157 (302)
Transgenic Zebrafish as a Novel Animal Model to Study Tauopathies and Other Neurodegenerative Disorders in vivo [PDF]
Our ageing society is confronted with a dramatic increase in patients suffering from tauopathies such as Alzheimer's disease, frontotemporal dementia and others.
Haass, Christian +2 more
core +1 more source
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova +25 more
wiley +1 more source
Guidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear.
Abigail Beard, Shannon C. Trotter
doaj +1 more source
The specificities of small molecule inhibitors of the TGF beta and BMP pathways [PDF]
Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been
Sapkota, Gopal P. +2 more
core +3 more sources
[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich +19 more
wiley +1 more source
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P. +6 more
core +4 more sources
Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez +10 more
wiley +1 more source
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T +13 more
core +2 more sources
A long‐lived, five‐cell‐type human neurovascular (PENTA) model recreates vascular disorganization and incomplete repair after traumatic brain injury (TBI). By integrating endothelial, glial, neuronal, and immune components within a 3D scaffold, the platform enables time‐resolved analysis of neurovascular remodeling and provides a human‐relevant system ...
Daniel S. Hinrichsen +6 more
wiley +1 more source
Janus Kinase inhibitors in dermatology: a review
Janus Kinases (JAKs) are a subset of cytoplasmic protein tyrosine kinases (TYK), crucial for the initiation of signaling pathways activated by cytokines through phosphorylation and activation of the signal transducer and activator of transcription (STAT)
Bárbara Vieira-Granja, Sofia Magina
doaj

